Clinical trials
catalyst calendar across sponsors →Studies where KARD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional
Held by 10 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, MARSHALL WACE, LLP, Hudson Bay Capital Management LP, +5 more) · FINRA short interest 6.7 days to cover (settled 2026-07-31) · insider 90d: 3 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated CardiomyopathyNCT07771465Frequency and severity of treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 3 | Not yet recruiting | Drug: Danicamtiv | Symptomatic Genetic Dilated Cardiomyopathy (DCM) | 332 | Nov 2032 | ≤ 2,295 d | 2026-08-18 |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled StudyNCT07001800(Part A) Change in Aortic Valve Calcium (AVC) score as assessed by non-contrast CT from baseline to Week 24Randomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: Ataciguat, Placebo | Moderate Aortic Valve Stenosis | 1,276 | 2028-08-31 | in 743 d | 2026-07-06 |
| A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated CardiomyopathyNCT07210723Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in Cohort 1Randomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: danicamtiv, Placebo | Symptomatic Genetic Dilated Cardiomyopathy | 332 | Sep 2027 | ≤ 407 d | 2026-08-04 |
| Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe HypertensionNCT07511361Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptionsRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Tonlamarsen, Placebo | Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency | 140 | Dec 2026 | ≤ 134 d | 2026-07-01 |
| A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)NCT06864104To assess the effect of tonlamarsen on plasma angiotensinogen (AGT) levelsRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Tonlamarsen, Placebo | Hypertension | 206 | 2026-01-12actual | — | 2026-03-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19